AR080088A1 - Composiciones y metodos para tratar, reducir, mejorar, aliviar o inhibir el avance de la neovascularizacion ocular patogenica.compuesto" - Google Patents
Composiciones y metodos para tratar, reducir, mejorar, aliviar o inhibir el avance de la neovascularizacion ocular patogenica.compuesto"Info
- Publication number
- AR080088A1 AR080088A1 ARP110100321A ARP110100321A AR080088A1 AR 080088 A1 AR080088 A1 AR 080088A1 AR P110100321 A ARP110100321 A AR P110100321A AR P110100321 A ARP110100321 A AR P110100321A AR 080088 A1 AR080088 A1 AR 080088A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- radical
- unsubstituted
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Una composicion para tratar, reducir, mejorar o inhibir el avance de la neovascularizacion ocular patologica en un sujeto, composicion que comprende: (a) un antagonista del receptor de integrina o vitronectina que tiene Formula (1) en donde G representa un grupo arilo o heteoarilo sustituido o no sustituido; grupo heterociclo sustituido o no sustituido; R7R8N-C(=NR6)-NH-CQ-A- NH-CO-; A-NH-CH2-; en donde A representa un grupo arilo, heteroarilo o heterociclo, no sustituido o sustituido con uno o varios grupos R9 R1 representa un átomo de hidrogeno; un átomo de halogeno, un grupo nitro; grupo alquil(C1-C4) alcoxi(C1-C4)-; Ar(C5-C,4)-; Ar(C5-Cl4)alquil-(clc4); un radical amino no sustituido o monosustituido o disustitu ido con un radical alquilo y / o un radical acilo que contiene 1 a 4 átomos de carbono, un grupo -(CH2)0..2- C(O)0R5 o un grupo -(CH2)o..2-0R5 R2 representa un átomo de hidrogeno; un átomo de halogeno; un grupo nitro; un radical alquilo que contiene 1 a 4 átomos de carbono; alcoxi(C1-c4); un radical amino no sustituido o monosustituido o disustjtujdo con un alquilo y / o un acilo que contiene 1 a 4 átomos de carbono; un grupo -(CH2)02-C(O)0R5 o un grupo -(CH2)02..QR5 R3 representa un átomo de hidrogeno, un radical -C(O)0R5, un radical - S02R5, o un sistema monocíclico o policíclico que comprende un sistema anular aromático o no aromático de 4 a 10 miembros, el anillo o por lo menos uno de los anillos contiene 1 a 4 heteroátomos escogidos entre N, O o S, no sustituido o sustituido con uno o varios radicales R9, R4 representa OH; alcoxi-(C1-C8)-; Ar-(C5-C,4)-alcoxi-(C1 -C4)-; ariloxi-(C5- C14)-; cicloalquiloxi-(C3-C12)-; cicloalquil-(C3-C12)-alquiloxi-(C1-C4)-; alquil-(C1-C8)- carboniloxi-alquiloxi(C1-C4)-; Ar-(C5-C14)-alquil-(C1-C4)-carboniloxi-alquiloxi-(C1- C4)-; dialquíl-(C1-C8)-aminocarbonilmetiloxi-; Ar-(C5-C14)-dialquil-(C1-C4)- 0 aminocarbonilmetiloxi-; un radical amino no sustituido o monosustituido o disustituido con un radical alquil-(C1-C4)- y / o Ar-(C5-C14)- y / o Ar-(C5-C14)-alquil- (C1-C4)- y / o un radical acil-(C1-C5)-; o el restante de ácido aspártico (D) o leucina (L); R5 representa alquil-(C1-C8)-; alquil-(Ci-C8)-C(O)O-alquil-(C1-C8)-; alquil15 (C1-C8)-S(O)(O)-alquil-(C1-C8)-; Ar-(C5-C14)-; Ar-(C5-C14)-alquil-(C1-C4)-; Ar-(C5- C14)-C(O)O-alquil-(C1-C4)-; cicloalquil-(C3-C12)-; cicloalquil-(C3-C12)-alquil-(C1-C4)-; bicicloalquil-alquil-(C1-C4)-; tricicloalquil-alquil-(C1-C4)-; dichos radicles Ar, alquilo, cicloalquilo, bicicloalquilo y tricicloalquilo no están sustituidos o están sustituidos con uno o varios grupos R9 20 R6 representa un átomo de hidrogeno; un grupo hidroxilo; nitro; alquil-(C1- C6)-O-C(O)-; alquil-(Ci-C6)-O-C(O)O-; R7 y R8, independientemente entre sí, representan un átomo de hidrogeno o un radical alquil-(C,-C6)- no sustituido o sustituido con R9 R9 representa halogeno; amino; nitro; hidroxilo; alcoxi (Ci-C4); alquiltio (C1-. 25 C4); carboxi; alquiloxicarbonilo (C,-C4); alquilo (C1-C8) no sustituido o sustituido con uno o varios átomos de halogeno; Ar (C5-C14); Ar (C5-C14)-alquil-(C1-C4); o uno o varios isomeros de un compuesto que tiene Formula 1, solos o en mezcla, una sal, éster, hidrato, solvato, clatrato, enantiomero o polimorfo farmacéuticamente aceptable de estos; y (b) un inhibidor de VEGF-A. Reivindicacion 2: La composicion de acuerdo con la reivindicacion 1, en donde el inhibidor de VEGF-A comprende un anticuerpo anti-VEGF-A. Reivindicacion 3: La composicion de acuerdo con la reivindicacion 2, en donde el inhibidor de VEGF-A comprende bevacizumab, ranibizumab, o una combinacion de estos. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 2, en donde el inhibidor de VEGF-A comprende un aptámero de VEGF-A. Reivindicacion 5: La composicion de acuerdo con la reivindicacion 2, que además comprende un agente antiinflamatorio. Reivindicacion 6: La composicion de acuerdo con la reivindicacion 5, en donde el agente antiinflamatorio comprende un material seleccionado del grupo formado por DAINE, ligandos de PPAR, combinaciones de estos, y sus mezclas. Reivindicacion 9: La composicion de acuerdo con la reivindicacion 9, en donde la neovascularizacion ocular patologica se selecciona del grupo integrado por: retinopatía diabética (ôRDö), degeneracion macular relacionada con la edad (ôDMREö) seca, DMRE humeda, edema macular diabético (ôEMDö), desprendimiento de retina, uveitis, posterior, neovascularizacion de la cornea, neovascularizacion del iris, y combinacion de estos. Reivindicacion 13: La composicion de acuerdo con la reivindicacion 7, en donde la composicion comprende un dispositivo oftálmico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30013810P | 2010-02-01 | 2010-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080088A1 true AR080088A1 (es) | 2012-03-14 |
Family
ID=44341888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100321A AR080088A1 (es) | 2010-02-01 | 2011-01-31 | Composiciones y metodos para tratar, reducir, mejorar, aliviar o inhibir el avance de la neovascularizacion ocular patogenica.compuesto" |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110189174A1 (es) |
AR (1) | AR080088A1 (es) |
TW (1) | TW201136915A (es) |
WO (1) | WO2011094285A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110237605A1 (en) * | 2010-03-26 | 2011-09-29 | Eric Phillips | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative |
BR112016014404A2 (pt) * | 2013-12-18 | 2017-08-08 | Gnt Llc | Composições e métodos para tratamento de glaucoma |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
IL290457B1 (en) | 2015-12-30 | 2024-10-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
KR20190093214A (ko) | 2016-12-13 | 2019-08-08 | 베타 테라퓨틱스 피티와이 리미티드 | 헤파라나제 억제제 및 그의 용도 |
US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
WO2020022787A1 (ko) * | 2018-07-24 | 2020-01-30 | 삼진제약주식회사 | Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물 |
HUE051802T2 (hu) | 2018-08-17 | 2021-03-29 | Oxurion NV | Integrin antagonisták |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021165206A1 (en) | 2020-02-19 | 2021-08-26 | Oxurion NV | Treatment of dry amd with integrin antagonists |
CN116059312A (zh) * | 2021-07-23 | 2023-05-05 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
WO2024073355A2 (en) * | 2022-09-26 | 2024-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for monitoring molecular biomarkers for aging and disease |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US6011020A (en) * | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US6147204A (en) * | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
AU1116297A (en) * | 1995-11-08 | 1997-05-29 | Immunex Corporation | Flk-1 binding protein |
EP0888310B1 (en) * | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US6426335B1 (en) * | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6242196B1 (en) * | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
AU4713499A (en) * | 1998-06-27 | 2000-01-17 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
WO2002062385A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt, Inc. | Method to prevent vision loss |
US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
US6958340B2 (en) * | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2003272471B2 (en) * | 2002-09-18 | 2010-10-07 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
FR2847254B1 (fr) * | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
JP2006525011A (ja) * | 2003-04-30 | 2006-11-09 | ファイザー・プロダクツ・インク | 白内障形成リスクに関するスクリーニング法 |
US7169802B2 (en) * | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
KR20050101458A (ko) * | 2004-04-19 | 2005-10-24 | 주식회사 하이닉스반도체 | 포토레지스트 세정액 조성물 및 이를 이용한 패턴 형성방법 |
BRPI0510485A (pt) * | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
FR2870541B1 (fr) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
MX2009001333A (es) * | 2006-08-07 | 2009-02-13 | Bausch & Lomb | Composiciones y metodos para tratar, reducir, mejorar o aliviar enfermedades oftalmicas del segmento posterior. |
US20090155176A1 (en) * | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
-
2011
- 2011-01-20 US US13/009,894 patent/US20110189174A1/en not_active Abandoned
- 2011-01-26 WO PCT/US2011/022539 patent/WO2011094285A1/en active Application Filing
- 2011-01-31 TW TW100103771A patent/TW201136915A/zh unknown
- 2011-01-31 AR ARP110100321A patent/AR080088A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2011094285A1 (en) | 2011-08-04 |
TW201136915A (en) | 2011-11-01 |
US20110189174A1 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080088A1 (es) | Composiciones y metodos para tratar, reducir, mejorar, aliviar o inhibir el avance de la neovascularizacion ocular patogenica.compuesto" | |
ECSP21091615A (es) | Derivados de benzisoxazol sulfonamida | |
PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
CO6440596A2 (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero de rapamicina | |
EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
MX2019011629A (es) | Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. | |
ECSP099496A (es) | Compuestos inhibidores de fosfofinosítido 3-quinasas y métodos de uso | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
BR112014014378A2 (pt) | composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico | |
BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
EA201270339A1 (ru) | Замещенные производные ксантина | |
CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
PE20150289A1 (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
EA201270755A1 (ru) | Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119 | |
PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
BR112020023115A2 (pt) | inibidores da via integrada de resposta a tensão | |
CO2020005486A2 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x | |
PE20211447A1 (es) | Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas | |
MX2022013273A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |